Current Status and Problems of Breast Cancer Treatment with Schizophrenia

Breast Cancer Care Pathways for Women with Preexisting Severe Mental Disorders: Evidence of Disparities in France?

“…A national study carried out in Japan, focusing on gastrointestinal cancer, found that patients with both cancer and schizophrenia were more likely to have advanced cancer upon admission than those without SMI, were less likely to receive surgical or endoscopic treatment after adjusting for cancer stage, and had higher in-hospital mortality within 30 days [ 28 ]. Another study, also conducted in Japan, but on breast cancer, found that patients with schizophrenia were less likely to receive chemotherapy or the recommended treatment compared to cancer patients without schizophrenia [ 29 ], while a study carried out at a large scale in Finland for the same type of cancer found a lower access to radiotherapy specifically for women with SMI [ 30 ]. In Canada, individuals with SMI and colorectal cancer were less likely to receive potentially curative surgical resection, as well as adjuvant radiation or chemotherapy [ 31 ].…”

Impact of pre‐existing mental health disorders on the receipt of guideline recommended cancer treatments: A systematic review

“…There were eight studies of women with breast cancer conducted across Finland, 15 Germany, 18 the US ( n = 2), 24,25 Denmark ( n = 2), 20,23 and Japan ( n = 2) 16,21 . Three studies found that breast cancer patients with schizophrenia, 20 depression 23 and any mental health illness 24 were less likely to be allocated to guideline recommended cancer treatment.…”

“…One study from Japan showed that women with PMHD underwent total mastectomy significantly more often (89% vs. 78%, p = 0.011) and underwent postoperative adjuvant chemotherapy (0% vs. 19%, p = 0.0031) and radiation therapy (2.2% vs. 18%, p = 0.0059) less often, compared with those women without PMHD 21 . Another study from Japan showed that women with a pre‐existing diagnosis of schizophrenia were significantly more likely to undergo mastectomy (84.3% vs. 63.2%, p = 0.0024) and less often received chemotherapy (40% vs. 88.7%, p < 0.0001), and guideline recommended cancer treatment (61.8% vs. 79.1%, p = 0.0004), compared with those women without schizophrenia 16 . However, there was no significant difference on radiation therapy (56.2% vs. 75.9%, p = 0.078), hormone therapy (84.2% vs. 90.6%, p = 0.20) and anti‐HER2 therapy (50% vs. 81.5%, p = 0.35) between the two groups in that study 16 .…”

“…Women with breast cancer and pre‐existing depression were more likely not to be allocated to guideline treatment (OR = 1.14, 95% CI = 1.03–1.27), 23 while those with schizophrenia and psychiatric disorders (61.8% vs. 79.1%, p = 0.0004 16 ; OR = 1.50, 95% CI = 1.15–1.94), 20 or non‐specific PMHD (OR = 0.79, 95% CI = 0.65–0.97) 24 were less likely to receive guideline treatment. This was especially so for women with depression who were more likely not to be allocated to curative intent (OR = 1.19, 95% CI = 1.06–1.33) 25 and women with schizophrenia who less often underwent chemotherapy (40.0% vs. 88.7%, p < 0.0001) 16 . In addition, women with non‐specific PMHD received less postoperative adjuvant chemotherapy (0% vs. 19%, p = 0.0031) and radiation therapy (2.2% vs. 18%, p = 0.0059) but underwent more mastectomies (78% vs. 59%, p = 0.011) 21 .…”

γ-Glutamyltranspeptidase and pH based “AND” logic gate fluorescent probe for orthotopic breast tumor imaging

“…Breast cancer has gained significant attention due to its high incidence globally. 1,2 Total mastectomy is still the first line of surgical therapy, but the volume of breast tissue removed negatively affects the psychological and physical fitness of patients. 3,4 To reduce both the removed tissue and the chance of recurrence, accurate intraoperative localization of the tumor and its boundary is required.…”